Phase 3 N=12 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
Pulmonary Hypertension
Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=419 AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Anticancer Treatment
Primary: Progression Free Survival (PFS) by Investigator Assessment — 10.1; 4.4 Months — p=<0.001
Phase 3 N=554 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity
Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 24 Weeks — 0; -0.9 units on a scale — p=0.059
Phase 3 N=676 Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Chronic Plaque Type Psoriasis
Primary: Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16 — 79.0; 57.3 Percentage of…
Phase 3 N=54 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
Glaucoma, Neovascular
Primary: Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1 — -8.5; -4.9 mmHg — p=0.0644
Phase 3 N=746 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Hyperlipidemia
Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.8; -50.8 percent change — p=<0.001
Phase 3 N=768 Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Colorectal Neoplasms
Primary: Progression-Free Survival (PFS) by Central Review Assessment — 1.38; 1.51 Months — p=<0.0001
Phase 3 N=225 A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Major Depressive Disorder
Primary: MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate — 10; 11; 29; 5 Participants
Phase 3 N=835 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period — 0.290; 0.155 relapses/participant year of…
Phase 3 N=821 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks — 0.292; 0.156 relapses/participant year of treatment — p=<0.0001
Phase 3 N=658 A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) — 7.4; 3.8 months — p=<0.0001
Phase 3 N=872 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Psoriasis
Primary: Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From…
Phase 3 N=637 A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing
Colon Cleansing in Preparation for Colonoscopy
Primary: The Efficacy Rate Based on the Overall Colon Cleansing Effect as Assessed by the Independent Central Judging Committee Using the Japanese Colon Cleansing Scale — 97.7…
Phase 3 N=230 Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
ADHD · Growth
Primary: Change Score for Z-height Baseline to Endpoint — -.04; -.11 Z score
Phase 3 N=75 Scleroderma: Cyclophosphamide or Transplantation
Scleroderma, Systemic · Sclerosis · Autoimmune Disease
Primary: Global Rank Composite Score (GRCS) (Month 54, ITT) — 17.0; -6.0 Sum of subject-pair comparison scores — p=0.013